The strong interim data supports potential registrational path for cema-cel, which could lead to near-term value inflection for Cellectis via milestone triggers. Traders should monitor upcoming EFS data readouts in 2027–2028 and assess probability of BLA submission. Given the therapy’s favorable safety and outpatient profile, commercial potential appears enhanced compared to autologous CAR-Ts.
Price Chart
Executive Summary
Cellectis highlighted positive interim futility analysis results from Allogene's pivotal ALPHA3 trial of cema-cel, an allogeneic CAR-T therapy for large B-cell lymphoma. The data showed a 41.6% absolute improvement in MRD negativity versus observation, with strong safety and outpatient manageability. As the originator of the licensed therapy, Cellectis stands to benefit from up to $340M in milestone payments and low double-digit royalties if the product is commercialized.
Key Financial Metrics
Key Facts
- Interim futility analysis from Allogene's ALPHA3 trial showed 58.3% MRD negativity in the cema-cel arm vs. 16.7% in the observation arm (41.6% absolute difference).
- Cema-cel is derived from Cellectis' UCART19, the first allogeneic CAR-T, and is licensed to Servier and sublicensed to Allogene.
- No cases of CRS, ICANS, GvHD, or treatment-related serious adverse events were reported; most patients (10/12) were managed outpatient.
- Study enrollment expected to complete by end of 2027, with interim EFS analysis in mid-2027 and primary analysis in mid-2028.
- Cellectis is eligible for up to $340 million in development and sales milestones and low double-digit royalties on net sales.
Financial Impact
Up to $340 million in milestone payments and low double-digit royalties on future sales of cema-cel.
Risk Factors
- Interim data based on small patient numbers (n=24); may not predict final outcomes.
- Future results could differ materially due to clinical development risks, regulatory hurdles, or trial design challenges.
- Cellectis does not control development—dependent on Allogene and Servier for execution and regulatory progress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272912 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $0.9670 (+47.16%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $0.9670 (−47.16%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $0.9670 (−65.89%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $0.9670 (−67.77%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $0.9670 (−68.71%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $0.9670 (−69.59%) |
May 12, 2026 23w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $0.9670 (−75.58%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $0.9670 (−74.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers